

Panel Member Participation

During the meeting:



- Mute your device when not speaking
- Use the chat box to queue up questions/comments
- For technical assistance, please email your point of contact

Your Participation

Open and close your control panel

Join audio:

- Choose **Computer Audio** to listen through your computer (headset recommended)
- OR-
- Choose **Phone Call** and dial in using the information provided



Welcome!

The advisory panel meeting will begin promptly at 12:15 pm ET

Clinical Effectiveness and Decision Science

PCORI Virtual Advisory Panel Meeting

December 6, 2021 | 12:15–3:00 pm ET



Welcome & Introductions

Stanley Ip, MD

Interim Program Director,
Clinical Effectiveness and Decision Science

Kari Gali, DNP, APRN, PNP-BC

CEDS Advisory Panel Chair

Julie Eller, MPH Candidate

CEDS Advisory Panel Co-chair

Housekeeping

- Today's webinar is open to the public and is **being recorded**.
 - Meeting information can be found at www.pcori.org:
 - Meetings & Events → Advisory Panel Meetings → *Advisory Panel on Clinical Effectiveness and Decision Science Winter 2021 Meeting*
- No public comment period is scheduled.
- Please remember to **speak loudly** and **clearly into your microphone**.
- State your name and affiliation before you speak.
- Please avoid technical language in your discussion.
- As a reminder, please mute yourself when not speaking.

Conflict of Interest Statement



Disclosures of conflicts of interest of members of this panel are publicly available on PCORI's website and are required to be updated annually. Members of this panel are also reminded to update conflict of interest disclosures if the information has changed by contacting your staff representative.

If this panel will deliberate or take action on a manner that presents a conflict of interest for you, please inform the Chair so we can discuss how to address the issue. If you have questions about conflict of interest disclosures or recusals relating to you or others, please contact your staff representative.

CEDS Panel Leadership



- **Kari Gali, DNP, APRN, PNP-BC**
CEDS Advisory Panel Chair
- **Julie Eller, BS, MPH Candidate**
CEDS Advisory Panel Co-Chair
- **Holly Ramsawh, PhD**
Senior Program Officer, Clinical Effectiveness and Decision Science
- **Julia Song, MPH**
Program Associate, Clinical Effectiveness and Decision Science

CEDS Panel Chair and Co-Chair

Kari Gali, DNP, APRN, PNP-BC

Pediatric Nurse Practitioner, *Cleveland Clinic*

Representation: Clinicians
CEDS Advisory Panel Chair



Julie Eller, MPH Candidate

Representation: Patient Advocates/Patients
CEDS Advisory Panel Co-Chair



Agenda

| Time | Duration | Activity |
|----------|----------|--|
| 12:15 PM | 25 min | Welcome and Introductions |
| 12:40 PM | 20 min | CEDS Research Area Overview |
| 1:00 PM | 10 min | Break |
| 1:10 PM | 30 min | Strategic Planning: National Priorities for Health |
| 1:40 PM | 30 min | Update on IDD |
| 2:10 PM | 5 min | Break |
| 2:15 PM | 30 min | Update on MMM |
| 2:45 PM | 15 min | Closing Remarks |

CEDS Advisory Panel

Fall 2021 - Fall 2022

Members



CEDS Panel Members 2021



Patients, Caregiver Advocates, and Advocacy Organizations

- Helen M. Beady, EdD, Med
- Christina Nyquist, BA*
- Jennifer Olsen, DrPH*
- Michael Philbin, PhD
- Sarah Wang, BS*

Payers, Industry, and Policy Makers

- Adjoa Adofo Kyerematen, MS
- Danielle Bargo, MSc
- Eric Cannon, PharmD, FAMCP
- David Webster, MD, MBA
- Maureen White, MD, MS, MBA**

Clinicians and Researchers

- William Bennett, MD, MS
- Karen Giuliano, PhD, MBA, RN
- Lisa Goldman Rosas, PhD, MPH
- Timothy Gong, MD, FACC*
- Samantha Harden, PhD, RYT® 500
- Michael Hoerger, PhD*
- Susan Johnson, MBA, MS
- Joey Mattingly, PharmD, PhD, MBA
- Rick Rader, MD

* New panel members

**Panel member whose term ended August 2021

Farewell

**Thank you for your contributions to PCORI
and your service on the CEDS Advisory
Panel!**

- Maureen White, MD, MS MBA



CEDS Program Update

Holly Ramsawh, PhD

Senior Program Officer,
Clinical Effectiveness and Decision Science




Clinical Effectiveness and Decision Science



The **Clinical Effectiveness and Decision Science** (CEDS) program seeks to fill clinical information gaps by producing valid, trustworthy, and useful new evidence comparing the effectiveness of different clinical options. In situations where there already is adequate evidence, CEDS seeks approaches to raise patients' and caregivers' awareness of this information so they can make use of it in choosing the best option for them.

CEDS Overview




Assessment of Prevention,
Diagnosis, and Treatment Options




Improving
Healthcare Systems



Communication &
Dissemination
Research



Addressing
Disparities



Accelerating PCOR
and Methodological
Research

Research Awards: Current CEDS Portfolio



PCORI HAS AWARDED OVER

\$1 BILLION TO FUND 366

**COMPARATIVE EFFECTIVENESS STUDIES IN
CLINICAL EFFECTIVENESS AND DECISION SCIENCE**

As of June 2021

| Funding Mechanism | # of Projects |
|-------------------|---------------|
| Broad | 305 |
| Pragmatic | 22 |
| Targeted | 39 |

Note: Funded awards do not include MOU's, Pilot Projects, or IPD meta-analyses

New Research Awards

A green circle with a black outline containing the text "Recent Awards".

Recent Awards

4

Suicide Prevention: Brief Interventions for Youth
Targeted PFA Awards

3

Assessment of Options Broad PFA Awards

2

Improving Methods for PCOR Broad PFA Awards

1

Phased Large Awards for Comparative Effectiveness
Research (PLACER) **PFA Awards**

New Research Awards: A sampling

| Study Title | PI Name | Site | Cycle 3 2020 PCORI Funding Announcement (PFA) |
|---|--|--|---|
| <u>Treat-to-Target of Endoscopic Remission in Patients with Inflammatory Bowel Diseases in Symptomatic Remission: A Pragmatic Randomized Controlled Trial</u> | Siddharth Singh, MD, MS [Jason Hou, MD, MS] | Children's Hospital of Philadelphia | Broads |
| <u>New Methods for Planning Cluster Randomized Trials to Detect Treatment Effect Heterogeneity</u> | Michael Harhay, PhD, MPH, MA, MS | Trustees of the University of Pennsylvania | Methods |
| <u>Large Pragmatic Trial to Prevent Suicide Attempts, Deaths in Moderate-to-High Risk Youth</u> | Gregory Clarke, PhD [Courtney McCracken, PhD] | Mayo Clinic | PLACER |

Currently in Review: Cycle 1 2021



Awards Announced December 2021

- Broad: Improving Assessment of Options, Improving Methods
 - Special Areas of Emphasis:
 - Improving care transitions for those with intellectual and developmental disabilities (IDD)
 - Increasing Access to and Continuity of Patient-Centered Maternal Care
 - COVID-19
- Pragmatic Clinical Studies

Currently in Review: Cycle 2 2021



Awards Announced March 2022

- Broad: Improving Assessment of Options, Improving Methods
 - Special Areas of Emphasis:
 - Improving care transitions for those with intellectual and developmental disabilities (IDD)
 - Increasing Access to and Continuity of Patient-Centered Maternal Care
 - COVID-19
- Pragmatic Clinical Studies
- Targeted PFAs
 - Urinary Incontinence
 - Maternal Morbidity and Mortality
 - Intellectual and Developmental Disabilities

Upcoming: Cycle 3 2021



Awards Announced July 2022

- Broad: Improving Assessment of Options, Improving Methods
 - Special Areas of Emphasis:
 - Improving care transitions for those with intellectual and developmental disabilities (IDD)
 - Increasing Access to and Continuity of Patient-Centered Maternal Care
 - COVID-19
- Phased Large Awards for Comparative Effectiveness Research
- Targeted PFAs
 - Comparative Effectiveness of Multimodal Interventions to Prevent Osteoporotic Fractures
 - Healthy Aging: Optimizing Physical and Mental Functioning Across the Aging Continuum
 - Comparative Effectiveness of Novel Pharmacologic and Evidence-Based Nonpharmacologic Treatments for Migraine Prevention

BREAK



10 min

Please return at 1:10 pm ET

Strategic Planning: Proposed Research Agenda

Kimberly Bailey, MS

Associate Director,
Clinical Effectiveness and Decision Science




Scope of Strategic Planning Activities



Strategic Planning

- **National Priorities for Health**
- **Research Agenda**
- Strategic principles for PCORnet® phase 3
- Methodology Committee focus for PCORI's next phase
- Commitment Planning and strategies to increase funding
- Scenario Planning based on the changes in landscape and environment
- Priorities from reauthorizing law
 - Maternal morbidity and mortality
 - Intellectual and developmental disabilities
 - Full range of outcomes data
- Monitoring progress and measuring success

Adopted National Priorities for Health



Research Agenda: A Component of the Strategic Plan



- The **strategic plan** centers on achieving the National Priorities for Health, and the Research Agenda is one major component of the plan. The strategic plan aims to describe all the various components and present a cohesive vision for PCORI's future activities.
- The **Research Agenda** provides a framework for achieving progress on the National Priorities for Health specifically through the strategy of funding comparative clinical effectiveness research (CER). The Research Agenda helps guide the development of a continuously relevant **Research Project Agenda** via an on-going, stakeholder-engaged process.
- PCORI utilizes other strategies in addition to funding CER (for example, Dissemination & Implementation) to achieve the National Priorities for Health, and these will be described in other components of the strategic plan.

Creation of the Research Agenda



Proposed Research Agenda

- Fund research that fills patient- and stakeholder-prioritized evidence gaps and is representative of diverse patient populations and settings
- Fund research that aims to achieve health equity and eliminate health and healthcare disparities
- Fund research that builds the evidence base for emerging interventions by leveraging the full range of data resources and partnerships
- Fund research that examines the diverse burdens and clinical and economic impacts important to patients and other stakeholders
- Fund research that focuses on health promotion and illness prevention by addressing health drivers that occur where people live, work, learn, and play
- Fund research that integrates implementation science and that advances approaches for communicating evidence so the public can access, understand, and act on research findings

Proposed Research Agenda and Examples for Supporting Context

Research Agenda Statement:

Fund research that fills patient- and stakeholder-prioritized evidence gaps and is representative of diverse patient populations and settings

Illustrative Examples

- Research on topics and outcomes of high relevance and value to patient and stakeholder communities that generates timely evidence to inform decisions
- Research that recruits study participants that are representative of communities most affected by conditions being studied and are representative of the diversity of the nation in order to understand potential differences in treatment effects and outcomes across populations
- Research that involves investigators that reflect the population or community where the research is conducted and for whom the research is intended

Research Agenda Statement:

Fund research that aims to achieve health equity and eliminate health and healthcare disparities

Illustrative Examples

- Research across conditions, populations, and subpopulations on topics where disparities in health outcomes occur
- Research on innovations for health systems that drive practice change to promote equitable care and eliminate discriminatory health care practices
- Research that supports and develops the talent of diverse, early career investigators and the health care workforce

Proposed Research Agenda and Examples for Supporting Context- Continued

Research Agenda Statement:

Fund research that builds the evidence base for emerging interventions by leveraging the full range of data resources and partnerships

Illustrative Examples

- Research that leverages evidence synthesis and stakeholder engagement to meet the evidentiary needs of federal, state, and local policymakers and stakeholders
- Research on innovations identified through relationships with federal partners including the FDA, CMS, NIH, VA, CDC, and AHRQ
- Research using optimized methods of data capture that are inclusive of diverse sources of real-world information (including patient-provided data)

Research Agenda Statement:

Fund research that examines the diverse burdens and clinical and economic impacts important to patients and other stakeholders

Illustrative Examples

- Research that engages patients, caregivers, and other key stakeholders in identifying important outcomes, unintended consequences, burdens, and economic impacts
- Research that assesses the full range of factors that influence health outcomes, such as patient preferences, economic issues, practice variation, and disparities in the delivery of care

Proposed Research Agenda and Examples for Supporting Context- Continued

Research Agenda Statement:

Fund research that focuses on health promotion and illness prevention by addressing health drivers that occur where people live, work, learn, and play

Illustrative Examples

- Research in cross-sector collaboration with organizations with expertise in the social determinants of health (e.g., economic stability; education access and quality; health care access and quality; neighborhood and built environment; social and community context)
- Research on upstream topics such as social determinants of health, public health, and policies or programs that influence population-level health
- Research that examines the use of and investment in health-promoting resources in the community

Research Agenda Statement:

Fund research that integrates implementation science and that advances approaches for communicating evidence so the public can access, understand, and act on research findings

Illustrative Examples

- Research that studies the effectiveness of ways to get information to the right people, at the right time, in the right way that addresses cultural and other tailoring, modes of communication, and appropriate messengers for specific populations
- Research on approaches for rapid dissemination of evidence to inform the immediate decisional needs of patients, clinicians, health systems, and other stakeholders
- Research on the effectiveness of implementation strategies that have potential for accelerating the uptake of evidence into practice
- Research that assesses methods for explaining uncertainty, applicability, and communicating risk, including approaches for tailoring these methods for diverse populations

Hearing from the Panel

Discussion Questions

1. How might the proposed Research Agenda meet future needs for PCORI's strategy of funding CER?
2. How could the proposed Research Agenda support a research portfolio that is inclusive of this panel's topics of interest?
3. Is there an important research area that you would like to see better reflected in the proposed Research Agenda?
4. What kinds of research portfolios will be important to support the specific Statements?



Proposed Research Agenda

- Fund research that fills patient- and stakeholder-prioritized evidence gaps and is representative of diverse patient populations and settings
- Fund research that aims to achieve health equity and eliminate health and healthcare disparities
- Fund research that builds the evidence base for emerging interventions by leveraging the full range of data resources and partnerships
- Fund research that examines the diverse burdens and clinical and economic impacts important to patients and other stakeholders
- Fund research that focuses on health promotion and illness prevention by addressing health drivers that occur where people live, work, learn, and play
- Fund research that integrates implementation science and that advances approaches for communicating evidence so the public can access, understand, and act on research findings

Intellectual and Developmental Disabilities

Amanda Barbeau, MPH

Program Officer,
Clinical Effectiveness and Decision Science

Meghan Warren, PT, MPH, PhD

Program Officer,
Clinical Effectiveness and Decision Science



Origins of IDD Prioritization

2019 – Congress reauthorizes PCORI – Amending legislation to specify two new national priority areas:

Maternal mortality

Individuals with intellectual and developmental disabilities



Implementation of mandate will include:

A **long-term commitment** to priority areas of investment

Ongoing opportunities for engagement to identify stakeholder driven topics and patient-centered outcomes



This means IDD is set as a national priority area by law, thus a long-term priority area of investment through broad funding announcements, special areas of emphasis funding announcements, and topic specific funding announcements

Long Term Investment **IDD as a Research Priority**

- PCORI has a dedicated IDD Workgroup that was created to guide PCORI's efforts in meeting the legislative mandate of IDD as a research priority.
- Over the ensuing years, this Workgroup will partner with stakeholders to develop and implement the research agenda to provide evidence to help neurodiverse individuals get the best care for them.




Defining purpose of the Workgroup

The IDD Workgroup was created to guide PCORI's efforts in meeting the legislative mandate of IDD as a research priority.

The goal of the IDD Workgroup is to develop and implement the research agenda to provide evidence to help patients with IDD and their caregivers and practitioners make informed decisions, improve healthcare delivery and outcomes, and reduce disparities.

Sub-groups of the IDD Workgroup

- **OVERSIGHT & STRATEGY** will set the overarching strategic objectives and provide general guidance to the IDD Workgroup at all levels of activity and funding product development.
- **MONITORING & EVALUATION** will identify existing IDD work in the PCORI portfolio and identify and maintain information on the portfolio going forward.
- **FUNDING PRODUCTS** will be tasked with developing research PFAs and other funding efforts from topic generation to Board approval and release of the funding announcement. This sub-group will also serve as a consultative partner for the development of Engagement Award PFAs.
- **STAKEHOLDER ENGAGEMENT** will lead the process of identifying and reaching out to stakeholders and coordinating any multi-stakeholder events.
- **EVIDENCE SURVEILLANCE & TOPIC PRODUCTION** will lead the effort to develop, vet, and prioritize IDD topics.
- **DISSEMINATION & COMMUNICATION** will lead the efforts to communicate with the public about PCORI's IDD portfolio and results, as well as with the research community for funding opportunities. The group will also lead efforts surrounding implementation awards based on evidence resulting from PCORI funded research.



PCORI's approach and work to date in supporting IDD research

A Multipronged Approach to Improving Health and Quality of Life for Neurodiverse Individuals



Funding high-priority research

- Full range of research awards and evidence synthesis products
- Identification of short and long-term evidence gaps and priorities

Dissemination and implementation activities

- Dissemination and implementation of PCORI-funded projects
- Other D&I activities

Building capacity for PCOR

- Engagement awards
- Community-building projects
- Workforce awards
- PCORnet infrastructure awards

Enhancing efficiency and research design

- Understanding and providing guidance on methodologic issues
- Increasing engagement in research

PCORI HAS AWARDED

\$77 MILLION **60**
TO FUND

comparative clinical effectiveness research
studies and research support projects with
a focus on **intellectual and
developmental disabilities**


AS OF OCTOBER 2021

*PCORI has also funded six Methods and Infrastructure awards related to IDD

Number of projects



Funding amounts



Funding High Priority Research:

Focused funding to address the needs of individuals with IDD



- **Improving Care Transitions for Individuals with IDD**
- **Comparative Effectiveness of Interventions Targeting Mental Health Conditions in Individuals with IDD**

Background of Targeted PFA – Co-Occurring Mental Health Conditions



- **Priority Research Question:** What is the comparative effectiveness of evidence-based approaches (e.g., specific pharmacologic and behavioral interventions) that address mental health conditions in individuals with IDD?
 - Pharmacological, behavioral, other nonpharmacological or combination interventions administered via appropriate delivery modalities

Total Direct Costs:
Up to \$3M

Maximum Project Period:
3 years

- PCORI has allocated a total of up to **\$40 million** for this Targeted PFA

Next steps– Co-occurring IDD + Mental Health

- Merit Review for Cycle 2, 2021 Targeted PFA: December 2021
- Reissued Targeted PFA for Cycle 1 2022
 - Stakeholder workshops were held to refine the tPFA
 - Self-Advocates: 9/30/21
 - Clinicians/Researchers: 10/21/21

Building Capacity for PCOR/CER in IDD: Engagement Award Special Cycle



Special Cycle Funding Announcement to support projects that enable organizations and communities to build their capacity and skills to participate across all phases of the PCOR/CER process on topics that address health outcomes related to IDD on topics such as:

- Addressing health equity and advancing IDD health outcomes for vulnerable populations
- Leveraging community-based and patient-centered models of care delivery
- Challenges related to clinical care delivery and access
- Telehealth solutions
- Transition to adulthood
- Caregiver needs and access to wraparound support
- Patient needs and preferences

**13 projects
totaling
nearly \$4M
to date**

Stakeholder Engagement

Stakeholder



- To date, we have engaged 23 researchers and organizations representing
 - Patients and self-advocates
 - Caregivers
 - Clinicians
 - Researchers
 - PCORI awardees
- Representing groups working with people with autism, Down syndrome, ADHD, and other IDD

Self-Advocate Stakeholder Workshop



A 90-minute workshop with 8 self-advocates

Themes

- Significant barriers to accessing care
 - Difficulty finding providers who were willing to treat someone with an IDD
 - Providers not accepting their insurance
 - Lack of direct support professionals
- Needing to be seen as individuals with unique goals and concerns, not as diagnoses
- Importance of strong support systems

Read the summary [here](#)

Clinician/Researcher Workshop

A workshop with 11 experts

Themes:

- Few efficacious treatments for some conditions
- Clinical (or non-clinical use) considerations for the selection of comparators
- Systems level interventions may be more appropriate in some cases
- Challenges to conducting research with IDD populations include IRB requirements, enrollment, and randomization hesitancies
- Consideration for mental health targets that don't meet criteria for psychiatric disorder, but still have a large impact on quality of life

Watch the recording [here](#)

31 external attendees and 13 PCORI staff joined to listen to the discussion


Interested in funded studies?

<https://www.pcori.org/explore-our-portfolio>

Help us set priorities: How to
get involved

Suggest a Research Topic

- We want to hear your thoughts about which questions most urgently need answering. We've created a short survey to hear from you about research topics you feel are important.
- Take your phone & use your camera app to hover over the QR code to the right to access the survey.
- You can also access the survey at:
<https://survey.alchemer.com/s3/6594506/Community-Priorities-on-Intellectual-and-or-Developmental-Disabilities-Research>



Contact IDD Workgroup

IDDPCORI@PCORI.org



BREAK



5 min

Please return at 2:15 pm ET

Maternal Morbidity and Mortality (MMM)

Hillary Bracken, PhD

Program Officer, Healthcare Delivery and
Disparities Research

Els Houtsmuller, PhD

Associate Director, Healthcare Delivery and
Disparities Research



PCORI's Commitment to Maternal Health



Congress reauthorizes PCORI – Amending legislation to specify new national research priority areas:

- Maternal mortality
- Individuals with intellectual and developmental disabilities

Special Area of Emphasis in Broad Funding Announcement:
Increasing Access to and Continuity of Patient-Centered Maternal Care

Evidence Synthesis:

- Postpartum care
- Telehealth
- Hypertensive Disorders of Pregnancy

2021 PCORI Annual Meeting
“Meaningful Stakeholder Engagement for Equitable Maternal Health Outcomes”

Breakout Session

Targeted funding announcement:
Improving Postpartum Maternal Outcomes

2019

2020

2021

Maternal Morbidity and Mortality **PORTFOLIO SPOTLIGHT**



PCORI HAS AWARDED

\$111 MILLION **57**
TO FUND

comparative clinical effectiveness research
studies and research support projects with
a focus on **maternal mortality and
morbidity**

AS OF OCTOBER 2021

Maternal Morbidity and Mortality


PORTFOLIO SPOTLIGHT



Number of projects




Funding amounts



*CER studies include 2 MOUs with AHRQ

Maternal Mortality Framework: More than just pregnancy and delivery



PCORI's Stakeholder-Driven Process for CER



Broad Special Area of Emphasis:

Increasing Access to Patient- Centered Maternal Care



Highlights: Increasing Access to and Continuity of Patient-Centered Maternal Care

3

Studies
\$26 million

Comparisons:

- System-level strategies
 - Data accountability (maternal warning system & disparities dashboard)
 - Practice facilitation
 - Racial equity training
- Provider or patient facing interventions
 - Racially-concordant doula, mental health or midwifery care
 - Group prenatal care
 - Home blood pressure monitoring and interactive obesity treatment

Outcomes:

- Maternal morbidity, changes in maternal blood pressure, body weight, infant low birth weight
- Patient engagement, receipt of respectful care, experience of racism

STUDY PROFILE

The Path to Optimal Black Maternal Heart Health: Comparing Two CVD Risk Reduction Interventions



What This Study Does

- Compares two multilevel CVD risk reduction interventions for Black birthing people with obesity and/or hypertension

Comparators

- **Remote Patient Monitoring (RPM):** Home blood pressure telemonitoring + interactive obesity treatment + anti-racism training of health systems providers and staff and patient feedback to inform respectful care
- **RPM+:** RPM plus a triad of racially-concordant care: community doula care, mental health services and lactation support

Design

- Hybrid type I pragmatic randomized effectiveness trial (n=432)

Key Outcomes

- Changes in maternal blood pressure and body weight at 6 weeks and 1 year postpartum

Engagement

Study leadership is an equitable partnership of an academic physician-researcher and community-based Black provider who herself experienced heart health complications in her pregnancy, along with three other patient investigators.

Why It Matters

This study will help Black women with obesity and/or high blood pressure make informed decisions about the use of community doulas, lactation professionals, and psychotherapists as part of their care to reduce risks for heart disease during pregnancy or postpartum.

PI: Sharon Herring, MD, MPH
Temple University

STUDY PROFILE

Black midwives for Black women: Maternity care to improve trust and attenuate structural racism

What This Study Does

- Examines a culturally-adapted, patient-centered approach to prenatal and postnatal care to lead to more effective engagement among Black pregnant and postpartum people

Comparators

- **Melanated Group Midwifery Care:** 1) racially concordant midwifery care; 2) group prenatal care; 3) maternal care coordination; and 4) in-home, postpartum doula support.
- **Usual care:** scheduled visits with a midwife or obstetrician for physical exam and counseling

Design

- Hybrid type I pragmatic randomized effectiveness trial (n=432)

Key Outcomes

- Engagement in prenatal and postnatal care

Engagement

Conceptual model developed in collaboration with community partner, Melanated Midwives, and strong engagement of the community advisory board, including 12 Black mothers who experienced high-risk pregnancies, in the design and planned study implementation

Why It Matters

Policy makers, health systems, clinicians, and communities can draw on study findings when considering ways to improve maternity care for pregnant and postpartum women at high risk for maternal morbidity and mortality.

PI: Kylea Liese, PhD, CNM
University of Illinois, Chicago

Targeted Funding Announcement:

Improving Postpartum Care and Outcomes

Postpartum



Background of Targeted PFA – Improving Postpartum Maternal Outcomes

- **Priority Research Question:** What is the comparative effectiveness of multicomponent strategies to improve early detection of and timely care for complications up to six weeks postpartum in Black, American Indian/Alaska Native (AI/AN), Hispanic women, women who live in rural areas, and women with low/lower socioeconomic status (SES)?

Total Direct Costs:
Up to \$15M

Maximum Project Period:
5 years

- PCORI has allocated a total of up to **\$50 million** for this Targeted PFA
- Issued in Cycle 2 2021. Merit Review in December 2021

Stakeholder Engagement

Meaningful Stakeholder Engagement for Equitable Maternal Health Outcomes



2021 PCORI Virtual Annual Meeting *November 17-19, 2021*

Breakout session

A candid conversation about the barriers stakeholders face in addressing maternal morbidity and how PCORI and others can meaningfully support research on improved maternal health outcomes.

Panelists

Joia Crear-Perry, National Birth Equity Collaborative

NeKeshia Jones, Health Resources in Action

Karie E. Stewart, University of Chicago/Melanated Midwives

Karen Tabb Dina, University of Illinois /Perinatal Connect

[Recording of Breakout Session](#)

Contact MMM Workgroup

MMMpcori@pcori.org



Closing Remarks

Kari Gali
CEDS Chair

Julie Eller
CEDS Co-Chair

